Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer's Remicade Biosimilar: Sept. 15 Is Earliest Launch Date

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer and Celltrion agreed not to market Inflectra, their biosimilar to Janssen's blockbuster TNF-inhibitor, before mid-September barring certain circumstances.


Related Content

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues


Related Companies